Hinova's Clinical Trial Application of HP558 for the Treatment of gastrointestinal Tumors was Accepted by NMPA
On September 7, 2021, Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the National Medical Products Administration (NMPA) had accepted its application for clinical trials of HP558 injection.
HP558 is a First-in-class CD44v6 inhibitor developed by Amcure GmbH in Germany and licenced by Hinova. Hinova has exclusive rights to develop and commercialize HP558 in China (including Hong Kong, Macao and Taiwan) for all indications.
The Phase I clinical trial of HP558 has been completed in Europe, and no drugs with the same target for the same indication have entered clinical trials worldwide. Preclinical and clinical trials have shown that HP558 has good antitumor activity, safety and tolerability, and has potential therapeutic effects in gastrointestinal tumors. It can also be used in combination with chemotherapy or other target therapy agents for the treatment of a variety of advanced tumors.
About Hinova
Hinova is an international and clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D
